Use SurfactAway™ for Removal of Detergents During Viral Inactivation Using Solvent-detergent Methods.

Use SurfactAway™ for Removal of Detergents During Viral Inactivation Using Solvent-detergent Methods.

SurfactAway™ Triton and SurfactAway™ SDS are products by Biotech Support Group for detergent removal from protein samples. SurfactAway is very selective, virtually no cross-reactivity with other proteins with an economical new surface technology, not based on hydrophobic chromatography while removing >99% of detergent. Safe, efficient, and economical methods for removing virucidal material using SurfactAway ™ during the solvent-detergent removal method from virus-inactivated pooled plasma is a new application for SurfactAway ™.

Human plasma serves as a source for deriving valuable proteins and is a major source of coagulation factor replacement treatment for patients with clotting factor deficiency. For patients, donor plasma as either fresh frozen plasma or liquid plasma is tested for viral markers. However, to effectively reduce the risk of viral transmission, such plasma units often undergo viral inactivation using the solvent-detergent method.

What is solvent-detergent treatment method for viral inactivation and how is SurfactAway ™ used for removal of detergents?

• Viral inactivation of plasma or plasma derived protein products using a solvent based approach by detergent treatment is routinely used in the treatment of patients with deficiencies of coagulation factors including congenital single-factor deficiencies of factors I, V, VII, XI and XIII, and acquired multiple coagulation factor deficiencies; reversals of warfarin effect; and treatment of patients with thrombotic thrombocytopenic purpura (TTP).
• Solvent-detergent treatment is particularly effective for enveloped viruses such as Vesicular Stomatitis Virus (VSV), Pseudorabiesvirus (PRV), Semliki Forest Virus (SFV) and Bovine Diarrhoea Virus (BVDV). Solvent detergent treatment is primarily employed to reduce risk of transmission of viruses in fresh frozen plasma.

What are advantages of using SurfactAway ™ from Biotech Support Group than other competing products?

• Detergents can often interfere with protein analysis. SurfactAway™ offers a simple and fast method to remove SDS and non-ionic detergents such as Triton. Using SurfactAway™, the recovery of proteins is quantitative. SurfactAway™ SDS is especially designed for SDS removal and contains a conditioning buffer and a solid-phase binding suspension. A two-step, 10 minute process in a microfuge is all that’s required. Surfactaway™ Non-ionic, is a solid-phase suspension reagent, just add and centrifuge.
• SurfactAway ™ causes minimal disruption of vital lipid-based structure like biomembranes that surrounds and form a significant internal structural component of cells.
• Detergent removal by diafiltration, adsorption on chromatographic or affinity chromatographic supports, precipitation and lyophilization are cumbersome, expensive, time consuming, and result in potential loss of vital components of plasma.
• Removal of detergent by affinity or ion-exchange chromatography are lengthy, time consuming involve multiple steps & each recovery step is often associated with the loss of proteins of interest and hence result in lower yield.
• Removal of solvent/detergent can alternatively be performed by using carbon either in the form of activated carbon or charcoal. Carbon, however, is a nonspecific adsorbent, and when employed to adsorb virus inactivator and/or detergent, may also adsorb some of the important peptides components of interest from the plasma.
• Treatment with β-propiolactone, formaldehyde, sodium hypochlorite tend to denature the valuable protein components.

This new application of SurfactAway™ for detergent removal from protein samples using a simple method allows for plasma or plasma derivatives treated with solvent detergent methods during viral inactivation to be used for clinical applications. For more information about SurfactAway™, please visit: www.biotechsupportgroup.com

References

1. Extraction and identification of electroimmunoprecipitated proteins from agarose gels. Journal of Immunological Methods Volume 330, Issues 1-2, 31 January 2008, Pages 24-33
2. Guerrier, L., et al. (1995). Specific sorbent to remove solvent-detergent mixtures from virus-inactivated biological fluids. J. Chromatogr. B., (664), 119.
3. Van Holten, R. W., et al., “Incorporation of Viral Clearance Step into a Modified Cohen Fractionation”, Transfusion, Abstract Supplement, Oct. 1995, pp. S52, 13 Supplement, vol. 35.
4. Hilfenhause, J. et al., “Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses”. Transfusion, vol. 37, Sep. 1997, pp. 935-940.
5. Piet, M.P.J., et al., “The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation”. Transfusion 1990: 30:591-598.
6. Nellaiappan, K., et al., “Validation of a simple and sensitive gas chromatographic method for the analysis of tri-η-butyl phosphate from virally inactivated human immunoglobulin”. J. Chromatogr B Biomed Sci Appl.; 2001; Jun. 5; 757(1):181-189.
7. Karlsson, G., et al., “Determination of Triton X-100 in plasma-derived coagulation factor VIII and factor IX products by reversed-phase high-performance liquid chromatography”. J Chromatogr A 2002; Feb 8; 946(1-2):163-168.
8. Milwidsky, A., “A Rapid Method for the Production Control of the Non-ionic Component in Synthetic Detergents”, Analyst 1969; 94:377-386.
9. Josic D., et al., “Issues in the development of medical products based on human plasma1”. J. Chromatogr B 1997; 694:253-269.
10. Josic D., et al., “Purification of factor VIII and von Willebrand factor from human plasma by anion-exchange chromatography”. J. Chromatogr B 1994; 662(2):181-190.
11. Trescec, A., et al., “Removal of detergent and solvent from solvent-detergent-treated immunoglobulins”. J. Chromatogr A. 1999; 852(1):87-91.
12. Biesert L., “Virus validation studies of immunoglobulin preparations”, Clin. Exp. Rheumatol 1996, 14, Suppl. 15:547-52.
13. Biesert L., et al., “Solvent/Detergent Treatment of Human Plasma—A Very Robust Method for Virus Inactivation. Validated Virus Safety of OCTAPLAS®”, Vox Sang 1998, 74, Suppl. 1:207-212
14. Horowitz B., et al., Solvent/Detergent-Treated Plasma: A Virus-Inactivated Substitute for Fresh Frozen Plasma, Blood 1992; 79(3):826-831.
15. Horowitz B., et al., “Virus Inactivation by Solvent/detergent Treatment and the Manufacture of SD-plasma”. Vox Sang 1998; 74, Suppl. 1:203-206.
16. Horowitz B., et al., “Inactivation of Viruses in Labile Blood Derivatives”. I. Disruption of Lipid-enveloped Viruses by Tri(n-butyl)phosphate Detergent Combinations. Transfusion 1985; 25(6):516-22.
17. Troccoli. Noreen M., et al., “Removal of Viruses from Human Intravenous Immune Globulin by 35 nm Nanofiltration”, Biologicals (1998) 26, 321-329.
18. Hardy, R.R., “Purification and Characterization of Monoclonal Antibodies”, Handbook of Experimental Immunology in Four Volumes. D.M. Weir, Editor. Blackwell Scientific Publications. Oxford. pp. 13.1-13.13.
19. Bridonneau, P., et al., “Liquid Pasteurization of an Immunoglobulin Preparation with Stabilizer: Effects on its Biological and Biochemical Properties”, Vox Sang 1996:70:203-209.
20. Burnouf, T. et al., “Nanofiltration of plasma-derived biopharmaceutical products”. Haemophilia 2003; 9; 24-37.
21. Burnouf, T.. et al., “Reducing the Risk of Infection from Plasma Products: Specific Preventative Strategies”, Blood Reviews, 2000, 14:94-110
22. Burnouf, T., Value of Virus Filtration as a Method for Improving the Safety of Plasma Products, Vox Sang, 1996, 70:235-236.